Table 1.
Characteristics of treated and untreated SHROB rats at termination of study
| Group | Control (N = 14) | Captopril (N = 11) | Allylmercaptocaptopril (N = 9) |
|---|---|---|---|
| Age (days) | 203 ± 9 | 198 ± 4 | 206 ± 9 |
| Final body weight (g) | 540 ± 17 | 530 ± 17 | 470 ± 28 |
| Body mass index** | 11.6 ± 0.24 | 11.1 ± 0.28 | 10.2 ± 0.50* |
| Retroperitoneal fat pad (g) | 27 ± 2 | 27 ± 2 | 29 ± 2 |
| Gonadal fat pad (g) | 17 ± 1 | 17 ± 1 | 18 ± 1 |
| Mesenteric fat (g) | 14 ± 1 | 14 ± 1 | 13 ± 1 |
| Subscapular fat pad (g) | 33 ± 2 | 35 ± 1 | 34 ± 4 |
| Liver weight (g) | 16 ± 1.3 | 17 ± 1.1 | 15 ± 0.8 |
| Kidney weight (g) | 2.25 ± 0.12 | 2.34 ± 0.54 | 2.33 ± 0.51 |
| Heart weight (g) | 1.29 ± 0.05 | 1.19 ± 0.02 | 1.08 ± 0.07* |
| Left-ventricular wall thickness (mm) | 4.11 ± 0.21 | 3.81 ± 0.11 | 3.38 ± 0.06* |
| Plasma creatinine (mg/dL) | 0.95 ± 0.027 | 0.89 ± 0.029 | 0.84 ± 0.033* |
| Creatinine clearance rate (mL/min) | 1.2 ± 0.10 | 1.5 ± 0.163 | 1.3 ± 0.22 |
Data are mean ± SEM.
*
Significantly different from control SHROB rats, P < .05 according to Newman-Keuls test;
**
Body mass index is defined as kg body weight/(m naso–anal length2). The mean naso–anal length was 216 mm and did not differ between groups.